BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 25, 2005
View Archived Issues
Bayer claims novel vanilloid VR1 receptor antagonists for urological disorders
Read More
Recent patents report new treatments for depression, anxiety, psychotic disorders, etc.
Read More
BMS describes novel agents for osteoporosis, among other indications
Read More
Anxiolytic activity of ELB-139 in animal models described
Read More
OSI to acquire Eyetech Pharmaceuticals
Read More
Phase I trial results show the safety and pharmacokinetics of PRO-140 in healthy subjects
Read More
Fludelone is effective in preclinical models of multiple myeloma
Read More
Preclinical investigation of therapies for CRPS-I
Read More
Enrollment opens in phase II heparin replacement study for rNAPc2
Read More
BioSite obtains license for cardiovascular disease biomarker
Read More
Swedish Cancer Institute commences new phase II study in patients with BAC
Read More
Dyax and Merck KGaA enter license agreement for phage display libraries
Read More
Scios launches recommended use initiative for Natrecor
Read More
Endomorphin-2 and antiinflammatory cytokine gene therapy evoke analgesia
Read More
Preclinical evidence of antiallodynic effects of ACV-1
Read More
Chronic administration of CP-55940 relieves tumor-evoked mechanical hyperalgesia
Read More
Zaprinast alone and in combination with morphine facilitates antinociception
Read More
Copromotion agreement for Xifaxan ends
Read More
Lorus Therapeutics selects subclass of lead molecules from anticancer program
Read More
Canadian approval for phase III study of Multikine in head and neck cancer
Read More
Phase II/III MS study of MBP-8298 to be extended to Sweden
Read More
V-1003 enters phase II study for acute postoperative pain
Read More
Merck & Co. selects lead antibody for development for asthma
Read More
No drug interactions between rilpivirine and tenofovir disoproxil fumarate in healthy volunteers
Read More
Neuropeptide B modulates body weight homeostasis and inflammatory pain responses in mice
Read More
Aceon receives FDA approval for new indication
Read More
Cell Therapeutics decides on limited population for U.S. filing of Xyotax
Read More
Nevanac approved for pain and inflammation related to cataract surgery
Read More